Amyrt Pharmaceuticals PLC (LON:AMYT) has inked an exclusive distributor agreement for Lojuxta in Switzerland.
The tie-up is with RCC Pharma, a leading Swiss pharmaceutical company with expertise in early access programmes in rare and orphan diseases.
READ: Amryt Pharma inks exclusive Saudi Arabian distribution agreement for its Lojuxta and AP101 drugs
Lojuxta treats a rare and life-threatening condition called Homozygous Familial Hypercholesterolemia, which causes abnormally high levels of bad cholesterol.
Amryt estimates there are around 15 patients in Switzerland with HoFH.
The company has previously received requests from clinicians for access to Lojuxta from Swiss patients and the agreement means it will now be able to more effectively respond to such requests.
This latest distribution deal follows on from the agreement which covers Amryt’s products in Saudi Arabia, announced back in November.
Working on more partnerships
“This new distribution agreement with RCC marks another key step as we expand our footprint for Lojuxta across Europe, the Middle East, and North Africa,” said chief executive Joe Wiley.
“RCC is a leading Swiss company with particular expertise in rare diseases, and this agreement will help us to bring Lojuxta to patients suffering from HoFH in Switzerland.”
He added: “We continue to work on further partnerships across our licensed territories for Lojuxta, and look forward to announcing further developments.”